1. /20/EC. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities 1.5.2001.
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF
2. CDER (2008) Guidance for industry. Diabetes Mellitus: developing drugs and therapeutic biologics for treatment and prevention. Center for Drug Evaluation and Research, Feb 2008.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071624.pdf?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=PPARguidance2008&utm_content=2
3. CPMP III/3824/92 Rev.1. Committee for Proprietary Medicinal Products. Applicability of good laboratory practice. Commission of the European Communities
4. EMEA/341972/2006. CHMP SWP reflection paper on PPAR’s (Peroxisome Proliferator Activated Receptors), Sept 2006.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/11/WC500015479.pdf
5. Hayashi (1995) Duration of repeated dose studies to support first entry into humans. In: D’Arcy and Harron (eds) Proceedings of the third international conference on harmonization, Yokohama, pp 342–343